Nanobiotix (NBTX) issued the following statement in response to recent media speculation concerning intentions for a potential public take-over: “Nanobiotix states that, to the best of its knowledge, there is no such intention to acquire control of the Company, and no process or assessment is being conducted toward that end. Additionally, the Company has identified factual inaccuracies in this media report which are not consistent with the Company’s most recent public disclosures.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Updates Share Capital and Voting Rights as of February 28, 2026
- Nanobiotix Ramps Up Investor Outreach With March 2026 U.S. Conference Lineup
- Nanobiotix initiated with a Buy at TD Cowen
- Nanobiotix: Differentiated Radiotherapy Enhancer, J&J Partnership, and Multi-Indication Pipeline Undervalue Long-Term Upside, Supporting Buy Rating
